Aquestive Therapeutics (AQST) Gross Margin (2017 - 2026)

Aquestive Therapeutics' Gross Margin history runs 10 years deep, the most recent figure standing at 75.99% for Q1 2026.

• In Q1 2026, Gross Margin rose 1787.0% year-over-year to 75.99%; the TTM figure through Mar 2026 stood at 255.04% (down 32929.0% YoY), while the FY2025 annual figure was 1878.14%, down 194710.0% from the prior year.
• Gross Margin was 75.99% for Q1 2026 at Aquestive Therapeutics, down from 146.58% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 231.82% in Q4 2022 to a low of 34.48% in Q2 2022.
• Historically, Gross Margin has averaged 83.37% across 5 years, with a median of 65.66% in 2022.
• The sharpest annual moves came in 2022 and 2023: Gross Margin soared 16220 bps in 2022, then slumped 17333 bps in 2023.
• A 5-year view of Gross Margin shows it stood at 231.82% in 2022, then sank by 75 bps to 58.49% in 2023, then rose by 6 bps to 61.91% in 2024, then soared by 137 bps to 146.58% in 2025, then sank by 48 bps to 75.99% in 2026.
• The last three Gross Margin figures came in at 75.99% (Q1 2026), 146.58% (Q4 2025), and 64.82% (Q3 2025), per Business Quant data.